GHK-Cu + KPV + BPC-157 + TB-500 · Blend
Evidence gap: No established human blend-specific SC, oral or IM PK or absolute bioavailability. Component data do not resolve the combination.
Open in the interactive library →Compare with other compounds →
Assumed composition: 50 mg GHK-Cu + 10 mg each KPV, BPC-157 and TB-500 (80 mg total).
Context: Online proposals; no controlled blend trial identified in the source audit.
Limitations: Total blend mass differs from GHK-Cu mass. Audit found an inconsistent PeptaBase volume calculation.
Research Stacks proposes escalating the total blend.
Context: Commercial educational schedule, not a dose-response study.
Limitations: Audit found first-eight-week supply math exceeds three 80 mg vials; phases are unvalidated.
Forums contain variable proposals and reports of nausea, anxiety and stinging.
Context: Unverified anecdotes; no causal or incidence estimate.
Limitations: Syringe units alone are not a mass dose. These reports cannot establish safety or efficacy.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Assumed 80 mg blend; 50:10:10:10 mg ingredients
Attributed proposal / anecdote: Amount: 3.2 mg total blend: 2 mg GHK-Cu + 400 mcg each BPC-157, TB-500 and KPV; Frequency: Daily; Duration: Two to three months on / one month off; Route: SC; Formulation: Assumed 80 mg blend; 50:10:10:10 mg ingredients
Limitations: No controlled blend trial. The audited page’s stated volume did not match its component amounts; retain mass rather than treating syringe units as universal.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Assumed 80 mg 5:1:1:1 blend
Attributed proposal / anecdote: Amount: 1.6–4.8 mg total per injection; 3.2 mg described as standard; Frequency: Daily weeks 1–4; five times weekly weeks 5–8; two or three times weekly weeks 9–12; Duration: 12 weeks; Route: SC; Formulation: Assumed 80 mg 5:1:1:1 blend
Limitations: Unvalidated proposed activation/remodeling/maintenance phases; no dose-response trial.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Assumed 80 mg 5:1:1:1 blend
Attributed proposal / anecdote: Amount: 2 mg weeks 1–2; 4 mg weeks 3–4; 6 mg weeks 5–8; 4 mg weeks 9–12; all total-blend mass; Frequency: Daily; Duration: 12 weeks; Route: SC; Formulation: Assumed 80 mg 5:1:1:1 blend
Limitations: Proposed escalation, not a trial. The audited first eight weeks total 252 mg, exceeding three 80 mg vials.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation
Attributed proposal / anecdote: Amount: 2.67 mg total; 1.67 mg GHK-Cu + approximately 333 mcg each other ingredient; Frequency: Daily; Route: SC; Formulation: Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation
Limitations: Amounts are the prior audit’s concentration-dependent calculations, not outcome evidence or a universal syringe-volume recommendation.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation
Attributed proposal / anecdote: Amount: 3.2 mg total; 2 mg GHK-Cu + 400 mcg each other ingredient; Frequency: Daily; Route: SC; Formulation: Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation
Limitations: Amounts are the prior audit’s concentration-dependent calculations, not outcome evidence or a universal syringe-volume recommendation.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Assumed 80 mg 5:1:1:1 blend
Attributed proposal / anecdote: Amount: 2 mg total, potentially rising to 4 mg after several weeks; Frequency: Five times weekly; Route: SC; Formulation: Assumed 80 mg 5:1:1:1 blend
Limitations: Unverified proposed self-experiment. Exact escalation week and total duration are not given; no established successful outcome.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Prior audit calculated mass from 80 mg vial / 3 mL diluent
Attributed proposal / anecdote: Amount: 0.8 mg total; 500 mcg GHK-Cu + 100 mcg each other ingredient; Frequency: Five nights weekly; Route: SC; Formulation: Prior audit calculated mass from 80 mg vial / 3 mL diluent
Limitations: Unverified report includes nausea and initial anxiety; other account reports stinging. Cannot establish causation or event frequency.
These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.